NASDAQ:AUTL - Autolus Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Autolus Therapeutics Ltd - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.18 +0.69 (+6.58 %) (As of 02/17/2020 04:00 PM ET) Add Compare Today's Range$10.51Now: $11.18▼$11.1950-Day Range$9.66MA: $11.42▼$14.0952-Week Range$9.40Now: $11.18▼$32.84Volume191,041 shsAverage Volume281,944 shsMarket Capitalization$448.88 millionP/E RatioN/ADividend YieldN/ABeta0.89 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUTL Previous Symbol CUSIPN/A CIKN/A Webhttp://www.autolus.com/ Phone44-20-3829-6230Debt Debt-to-Equity Ratio0.09 Current Ratio12.65 Quick Ratio12.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.41 million Price / Sales318.35 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.42) Net Income$-12,860,000.00 Net Margins-3,576.93% Return on Equity-39.54% Return on Assets-33.58%Miscellaneous EmployeesN/A Outstanding Shares40,150,000Market Cap$448.88 million Next Earnings Date2/24/2020 (Estimated) OptionableNot Optionable Receive AUTL News and Ratings via Email Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AUTL Rates by TradingView Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions What is Autolus Therapeutics' stock symbol? Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL." How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics Ltd - (NASDAQ:AUTL) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.26. The firm earned $0.30 million during the quarter, compared to analysts' expectations of $2 million. Autolus Therapeutics had a negative net margin of 3,576.93% and a negative return on equity of 39.54%. View Autolus Therapeutics' Earnings History. When is Autolus Therapeutics' next earnings date? Autolus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Autolus Therapeutics. What price target have analysts set for AUTL? 3 Wall Street analysts have issued 1 year target prices for Autolus Therapeutics' shares. Their forecasts range from $24.00 to $26.00. On average, they expect Autolus Therapeutics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 123.6% from the stock's current price. View Analyst Price Targets for Autolus Therapeutics. What is the consensus analysts' recommendation for Autolus Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Autolus Therapeutics. What are Wall Street analysts saying about Autolus Therapeutics stock? Here are some recent quotes from research analysts about Autolus Therapeutics stock: 1. According to Zacks Investment Research, "Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. " (2/4/2020) 2. HC Wainwright analysts commented, "Our $24 price target, is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model, and reflects the recent dilution from the secondary offering. Our DCF is based on: beta of 1.50, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.4%, and tax rate of 15% beginning in FY 2028. Our rNPV for: (1) AUTO3 is $17; (2) AUTO1 is $4; and (3) AUTO4 is $3, which are derived from probability adjusted peak sales of: (1) $432M; (2) $150M; and (3) $96M, respectively." (9/12/2019) Has Autolus Therapeutics been receiving favorable news coverage? Media headlines about AUTL stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Autolus Therapeutics earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Autolus Therapeutics. Who are some of Autolus Therapeutics' key competitors? Some companies that are related to Autolus Therapeutics include Coherus Biosciences (CHRS), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Orchard Therapeutics (ORTX), NanoString Technologies (NSTG), Krystal Biotech (KRYS), Twist Bioscience (TWST), Adverum Biotechnologies (ADVM), BAVARIAN NORDIC/S (BVNRY), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Sangamo Therapeutics (SGMO) and DBV TECHNOLOGIE/S (DBVT). What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Crispr Therapeutics (CRSP), Nabriva Therapeutics (NBRV), Portola Pharmaceuticals (PTLA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), Agile Therapeutics (AGRX), GW Pharmaceuticals PLC- (GWPH), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT) and Uxin (UXIN). Who are Autolus Therapeutics' key executives? Autolus Therapeutics' management team includes the folowing people: Dr. Christian Martin Itin, Chairman & CEO (Age 55)Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 47)Mr. Andrew J. Oakley, CFO & Sr. VP (Age 57)Mr. Christopher Vann, Sr. VP & COO (Age 55)Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 54) When did Autolus Therapeutics IPO? (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Schroder Investment Management Group (5.22%), Marshall Wace LLP (1.69%), Victory Capital Management Inc. (0.86%), Point72 Asset Management L.P. (0.79%), Victory Capital Management Inc. (0.62%) and FMR LLC (0.53%). Which major investors are selling Autolus Therapeutics stock? AUTL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., Goldman Sachs Group Inc., Renaissance Technologies LLC and TD Asset Management Inc.. Which major investors are buying Autolus Therapeutics stock? AUTL stock was bought by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Point72 Asset Management L.P., Marshall Wace LLP, Victory Capital Management Inc., Alyeska Investment Group L.P., Vident Investment Advisory LLC, SG Americas Securities LLC and Ladenburg Thalmann Financial Services Inc.. How do I buy shares of Autolus Therapeutics? Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Autolus Therapeutics' stock price today? One share of AUTL stock can currently be purchased for approximately $11.18. How big of a company is Autolus Therapeutics? Autolus Therapeutics has a market capitalization of $448.88 million and generates $1.41 million in revenue each year. The company earns $-12,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. View Additional Information About Autolus Therapeutics. What is Autolus Therapeutics' official website? The official website for Autolus Therapeutics is http://www.autolus.com/. How can I contact Autolus Therapeutics? Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected] MarketBeat Community Rating for Autolus Therapeutics (NASDAQ AUTL)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 157 (Thanks for Voting!)Underperform Votes: 178 (Thanks for Voting!)Total Votes: 335MarketBeat's community ratings are surveys of what our community members think about Autolus Therapeutics and other stocks. Vote "Outperform" if you believe AUTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUTL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2020 by MarketBeat.com StaffFeatured Article: What are different types of coverage ratios?
